Evidence map›Paper›PMID 41902241›Full record

ArticleViruses2026

Serial Cell-Culture Passage of Severe Fever with Thrombocytopenia Syndrome Virus Attenuates Virulence and Confers Protective Immunity in Mice.

Jihee Kim, Young-Eui Kim, Hae Ji Kang, Jungsang Ryou, Hyuk Chu, Seok-Min Yun

Abstract read
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jihee KimDivision of Acute Viral Diseases, Center for Emerging Virus Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Republic of Korea.
Young-Eui KimDivision of Acute Viral Diseases, Center for Emerging Virus Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Republic of Korea.
Hae Ji KangDivision of Acute Viral Diseases, Center for Emerging Virus Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Republic of Korea.
Jungsang RyouDivision of Acute Viral Diseases, Center for Emerging Virus Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Republic of Korea.
Hyuk ChuDivision of Acute Viral Diseases, Center for Emerging Virus Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Republic of Korea.
Seok-Min YunDivision of Acute Viral Diseases, Center for Emerging Virus Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju-si 28159, Republic of Korea.ORCID 0000-0003-2087-3661

Funding

Korea National Institute of Health #2023-NI-016-02 and 6634-319-210-11
6 · The paper itself

Abstract

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne viral disease with high case-fatality rates in East Asia, yet no licensed vaccines are currently available. Here, we generated attenuated severe fever with thrombocytopenia syndrome virus (SFTSV) strains through serial passage in Huh-7 cells and evaluated their pathogenicity, immunogenicity, and protective efficacy. Attenuation candidates were selected based on reduced pathogenicity, estimated based on the median lethal dose (LD

Indexed as

PhlebovirusSevere Fever with Thrombocytopenia SyndromeViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralDisease Models, AnimalFemaleHumansImmunoglobulin GMiceMice, Inbred C57BLSerial PassageVaccines, AttenuatedViral LoadVirulenceAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GVaccines, AttenuatedViral Vaccinesattenuationimmunogenicitylive-attenuated vaccineprotective efficacyserial passagesevere fever with thrombocytopenia syndrome virus

Identifiers

PMID41902241
PMCPMC13030574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.